who is a candidate for glp 1 Eligible GLP-1 Medications for Weight Loss? What Are GLP-1 Medications &

The consensus statement recommends GLP-1/GIP therapy for: Adults with T1D who have overweight or obesity (BMI of 30 or higher, or 27 or higher with other health conditions) Adults with T1D who arent hitting their blood sugar goals with insulin alone, even at a healthy weight Teens and young adults with T1D who have overweight or obesity and arent reaching their targets on insulin or who are meeting targets but might still benefit If your BMI drops below 25, or was 25 or under when treatment started, your healthcare provider should check in regularly and may pause or stop the medication altogether

Specific GLP-1 agents have been shown to improve cardiovascular outcomes, and liraglutide, semaglutide (subcutaneous and oral), dulaglutide, and albiglutide consistently reduce the risk of MACE in people with T2D with established CVD or a high risk of CVD

Participants in the study discontinued treatment within 3 to 12 months, and researchers tracked their weight changes and subsequent treatments for one year after stopping the medication

The study compared three types of the medication: tirzepatide (better known under the brand names Zepbound and Mounjaro), semaglutide (sold as Wegovy and Ozempic), and liraglutide (aka Saxenda and Victoza)